Junghun Escitalopram Tablet 5 mg (Escitalopram Oxalate)

Adult administration

Safety has not been established for doses exceeding 20mg per day. This drug is administered once daily in the morning or evening, regardless of meals. Adults Major depressive disorder: The usual dosage is 10mg once daily. Depending on the patient's response, the dose may be increased to a maximum of 20mg per day. If the dose is to be increased to 20mg, the increase should be made at intervals of at least 1 week. In general, antidepressant effects take 2-4 weeks to develop. Even after symptoms have resolved, at least 6 months of drug therapy is needed to ensure the treatment effect. Panic disorder with or without agoraphobia: The recommended initial dosage is 5mg per day for 1 week, followed by an increase to 10mg per day. Depending on the patient's response, the dose may be increased to a maximum of 20mg per day. The maximum effect is seen after approximately 3 months. The safety and efficacy of long-term administration of this drug for more than 10 weeks in the treatment of panic disorder have not been systematically studied. The physician should periodically reassess each patient to determine the need for continued treatment. Social anxiety disorder: The usual dosage is 10mg once daily. In general, 2-4 weeks are needed for symptoms to improve. Thereafter, depending on the patient's response, the dose may be reduced to 5mg per day or increased to a maximum of 20mg per day. Social anxiety disorder is a condition with a chronic course, and continued treatment for 12 weeks is recommended to ensure the treatment effect. Long-term treatment in responding patients has been studied for 6 months and should be considered on an individual patient basis to prevent relapse. The usefulness of long-term treatment should be reassessed regularly. Generalized anxiety disorder: The initial dosage is 10mg once daily. Depending on the patient's response, the dose may be increased to a maximum of 20mg per day after at least 1 week of treatment. A long-term treatment study was conducted in patients who responded to 12 weeks of open-label treatment, with 20mg per day administered for at least 6 months. The physician should regularly reassess the usefulness of long-term treatment with this drug for each patient. Obsessive-compulsive disorder: The usual dosage is 10mg once daily. Depending on the patient's response, the dose may be increased to a maximum of 20mg per day. A long-term treatment study was conducted in patients who responded to 16 weeks of open-label treatment, with 10mg or 20mg per day administered for at least 24 weeks. Obsessive-compulsive disorder is a chronic condition; treatment should be continued for a sufficient period to ensure recovery from symptoms. When this drug is used long term, its usefulness and dosage should be regularly reassessed for each patient. Patients with renal impairment No dose adjustment is necessary in patients with mild or moderate renal impairment. Caution should be exercised in patients with severe renal impairment (CLCR < 30㎖/min). Patients with hepatic impairment An initial dose of 5mg per day for the first 2 weeks is recommended. Depending on the patient's response, the dose may be increased to 10mg per day. Discontinuation When discontinuing this drug, the dose should be gradually reduced over at least 1-2 weeks to avoid the possibility of withdrawal symptoms. Switching from MAO inhibitors used to treat psychiatric disorders At least 14 days must elapse between discontinuing an MAO inhibitor used to treat psychiatric disorders and starting treatment with this drug. Conversely, at least 14 days must elapse after discontinuing this drug before starting an MAO inhibitor to treat psychiatric disorders. Other MAO inhibitors such as linezolid or methylene blue It may be necessary to urgently administer linezolid or an intravenous methylene blue product to a patient already receiving this drug. If there is no alternative to linezolid or intravenous methylene blue and the benefits of treatment with linezolid or intravenous methylene blue are judged to outweigh the risk of serotonin syndrome in a particular patient, this drug may be discontinued immediately and linezolid or intravenous methylene blue administered. The patient should be monitored for symptoms of serotonin syndrome for 2 weeks after administration of linezolid or intravenous methylene blue, or until 24 hours after the last dose, whichever occurs first. Treatment with this drug may be resumed 24 hours after the last dose of linezolid or intravenous methylene blue. The risk associated with administration of methylene blue by non-intravenous routes (oral tablets or local injection) or intravenous administration of this drug at a dose of 1mg/kg or less is unclear.

This medication is an antidepressant used to treat psychiatric disorders like major depressive disorder. It is advised not to use this medication in children and adolescents under 18 years of age as safety and efficacy have not been established. When administering to young adults aged 18 to 24, there may be an increased risk of suicidal thoughts or behaviors, so the doctor must carefully assess the necessity and risks of treatment. During treatment with this medication, if symptoms of depression worsen, or if there is the emergence of suicidal thoughts, aggression, anxiety, or other abnormal behavioral changes, immediate medical observation and consultation are needed. This medication may cause serious side effects when combined with certain drugs, so it should not be taken with MAO inhibitors, pimavanserin, or drugs that prolong the QT interval. Patients with a history of closed-angle glaucoma or glaucoma should be cautious as this medication may dilate pupils and induce increased intraocular pressure. It is common for side effects such as insomnia, dizziness, nausea, and changes in appetite or libido to occur during the first 1 to 2 weeks of treatment, but symptoms often improve over time. There is an increased risk of seizures when using antidepressants; therefore, patients with a history of seizures should consult with their doctor before taking this medication. This medication can affect the heart, and patients with pre-existing heart disease or prolonged QT interval need to have their heart monitored. When discontinuing the medication, withdrawal symptoms such as dizziness, anxiety, and sleep disturbances may occur, so the dosage should be gradually reduced according to the doctor’s instructions. Pregnant or nursing women should consult their doctor before using this medication as it may affect the newborn; if nursing, either avoid use or discontinue breastfeeding. It is advisable to avoid alcohol consumption while taking this medication, and caution is needed when driving or operating machinery. In cases of overdose, symptoms involving the central nervous system and cardiovascular system may appear, requiring immediate emergency treatment. Finally, this medication should be kept out of reach of children and should not be transferred to another container.

Thrombocytopenia, anaphylactic reaction, inappropriate antidiuretic hormone secretion, hyperprolactinemia, decreased appetite, increased appetite, weight gain, weight loss, hyponatremia, anorexia, anxiety, restlessness, abnormal dreams, decreased libido, sexual dysfunction, bruxism, agitation, neuroticism, panic attacks, confusion, aggression, depersonalization, hallucinations, mania, suicidal ideation, suicidal behavior, insomnia, drowsiness, dizziness, perceptual disturbances, tremors, taste disorders, sleep disturbances, syncope, serotonin syndrome, movement disorders, dyskinesia, seizures, psychomotor agitation, mydriasis, visual impairment, tinnitus, tachycardia, bradycardia, prolonged QT interval on ECG, polymorphic ventricular tachycardia, ventricular arrhythmia, orthostatic hypotension, sinusitis, yawning, nosebleeds, nausea, diarrhea, constipation, vomiting, polydipsia, gastrointestinal bleeding, hepatitis, abnormal liver function tests, increased sweating, urticaria, hair loss, rash, itching, petechiae, angioedema, arthralgia, myalgia, rhabdomyolysis, urinary retention, ejaculation disorders, erectile dysfunction, uterine bleeding, menorrhagia, galactorrhea, postpartum hemorrhage, priapism, fatigue, fever, edema, headache, dry mouth, abdominal pain, indigestion, enteritis, sensory disturbances, cough, asthma, dyspnea, fractures, palpitations, hypertension, somnolence, aggressive response, hallucinations, chest pain, sedation, frequent urination, tremors, paralysis, extrapyramidal disorder, migraine, decreased libido, anorexia, visual hallucinations, insomnia, agitation, nausea, tremors, confusion, sweating, diarrhea, emotional instability, hypersensitivity, visual impairment, hypokalemia, hypomagnesemia, hypotension

This medication may be sensitive to light, so it should be stored in a container that blocks light. Additionally, it is best to store the medication at room temperature between 1 and 30 degrees Celsius. This storage method will help maintain the medication's effectiveness.

Appearance

White round film-coated tablet

Package unit

30 tablets/bottle, 100 tablets/bottle